Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 7/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 5/20 | 0.34 |
| ▸ | FEN1 | P39748 | 5/20 | 0.34 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11953553 | 0.84 | PDE10A (0.36) | PDE10AALOX5APFEN1TRPV3 | |
| SCHEMBL14765748 | 0.81 | GPR119 (0.39) | PDE10AALDH1A1LMNAMAPK1 | |
| SCHEMBL10091334 | 0.80 | PDE10A (0.36) | PDE10ATRPV3ALDH1A1KDM4ELMNA | |
| SCHEMBL12821173 | 0.80 | TRPV3 (0.35) | TRPV3 | |
| SCHEMBL11953546 | 0.79 | CYP3A4 (0.37) | TRPV3 | |
| SCHEMBL11943456 | 0.78 | PDE10A (0.33) | PDE10AALOX5APFEN1TRPV3 | |
| SCHEMBL12856682 | 0.77 | ALOX5AP (0.39) | ALOX5APFEN1 | |
| SCHEMBL20011091 | 0.77 | TRPV3 (0.39) | PDE10ATRPV3ALDH1A1SMN1; SMN2 | |
| SCHEMBL20614300 | 0.76 | ALOX5AP (0.38) | ALOX5APFEN1ALDH1A1KDM4E | |
| SCHEMBL11965808 | 0.76 | TRPV3 (0.39) | PDE10AALOX5APFEN1TRPV3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394294-B2 | Four-ring liquid crystal compound having lateral fluorine, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-03-12 | — | — | US | disclosed |
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | PDE10A 3804/4885ALOX5AP 1673/4885FEN1 3340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.